ALK receptor tyrosine kinase (ALK) rearrangement is a common driver mutation for patients with NSCLC. More than 20 other fusion partners for ALK in NSCLC have been reported.1 However, one patient with double ALK fusions simultaneously is still rare, and the double ALK fusions changing after treatment is also rarely reported. Here, a lung adenocarcinoma patient with EMAP like 4 (EML4)-ALK and protein kinase C beta (PRKCB)–ALK double fusion variant was presented who responded to crizotinib and showed the changes of two ALK fusions before and after treatment... In summary, this study is the first to describe a novel EML4-ALK, PRKCB-ALK double-ALK fusion lung adenocarcinoma patient who is sensitive to crizotinib. This is also the first study to describe a novel PRKCB-ALK fusion that may have promising efficacy by crizotinib treatment. In addition, the case also shows that liquid biopsy can provide more information of mutation to guide treatment and multiple liquid biopsy procedures can a..... READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.07.021
Authors: Jing Luo, Dejian Gu, Huasong Lu, Si Liu, Jinliang Kong